Consensus Tandem Diabetes Care, Inc.

Equities

TNDM

US8753722037

Market Closed - Nasdaq Other stock markets 04:30:00 2024-05-06 pm EDT			5-day change	1st Jan Change
43.5 ^USD	-2.73%		+17.41%	+47.06%

May. 03	Sector Update: Health Care Stocks Mixed in Afternoon Trading	MT
May. 03	Tandem Diabetes Care Shares Rise After Q1 Net Loss Shrinks, Sales Rise; Q2, 2024 Sales Guidance Set	MT

Evolution of the average Target Price on Tandem Diabetes Care, Inc.

Price target over the last 5 years

History of analyst recommendation changes

80966171c.yKZldXUwEnDU4l-FMAqAe8EH9brKb4d5q7Wzbl0l2DQ.q9BTDSNXeCmE02ngfUT5Lappgsy-N8gbwoH0JhVV7E7_3BMUMAZfArGmEg~4a38c3f402e90cf717af317218790027

Analyst Recommendations on Tandem Diabetes Care, Inc.

UBS Adjusts Price Target on Tandem Diabetes Care to $40 From $28, Maintains Neutral Rating	May. 03	MT
Wells Fargo Upgrades Tandem Diabetes Care to Overweight From Equalweight, Price Target is $45	Apr. 29	MT
Leerink Partners Upgrades Tandem Diabetes Care to Outperform Rating, Price Target is $45	Apr. 25	MT
Stifel Adjusts Price Target on Tandem Diabetes Care to $40 From $37, Maintains Buy Rating	Apr. 23	MT
Stifel Upgrades Tandem Diabetes Care to Buy From Hold, Adjusts Price Target to $37 From $24	Mar. 26	MT
Citigroup Raises Price Target on Tandem Diabetes Care to $31 From $25, Keeps Neutral Rating	Mar. 15	MT
UBS Raises Tandem Diabetes Care Price Target to $28 From $18, Maintains Neutral Rating	Jan. 22	MT
TD Cowen Raises Tandem Diabetes Care Price Target to $35 From $22, Maintains Outperform Rating	Jan. 18	MT
BofA Securities Cuts Price Target on Tandem Diabetes Care to $18 From $33, Keeps Underperform Rating	23-10-18	MT
Citigroup Cuts Tandem Diabetes Care's Price Target to $23 From $31, Keeps Neutral Rating	23-10-02	MT
Jefferies Adjusts Price Target on Tandem Diabetes Care to $45 From $47, Maintains Buy Rating	23-10-02	MT
Citigroup Adjusts Price Target on Tandem Diabetes Care to $31 From $33, Maintains Neutral Rating	23-08-21	MT
Baird Trims Price Target on Tandem Diabetes Care to $32 From $33, Maintains Neutral Rating	23-08-21	MT
UBS Adjusts Tandem Diabetes Care Price Target to $32 From $30, Maintains Neutral Rating	23-08-07	MT
Barclays Adjusts Price Target on Tandem Diabetes Care to $62 From $71, Keeps Overweight Rating	23-08-07	MT
Baird Adjusts Price Target on Tandem Diabetes Care to $33 From $38, Maintains Neutral Rating	23-08-04	MT
Citigroup Downgrades Tandem Diabetes Care to Neutral From Buy, Adjusts Price Target to $33 From $45	23-08-04	MT
UBS Adjusts Tandem Diabetes Care Price Target to $30 From $45, Maintains Neutral Rating	23-06-14	MT
Craig Hallum Adjusts Tandem Diabetes Care Price Target to $50 From $74, Maintains Buy Rating	23-06-13	MT
Citigroup Adjusts Price Target on Tandem Diabetes Care to $45 From $55, Keeps Buy Rating	23-06-05	MT
BofA Securities Downgrades Tandem Diabetes Care to Underperform From Neutral, Adjusts Price Target to $33 From $45	23-05-05	MT
Baird Adjusts Price Target on Tandem Diabetes Care to $38 From $40, Maintains Neutral Rating	23-05-04	MT
Wells Fargo Adjusts Price Target on Tandem Diabetes Care to $40 From $43, Maintains Equal-Weight Rating	23-05-04	MT
Raymond James Downgrades Tandem Diabetes Care to Market Perform From Outperform	23-04-24	MT
UBS Initiates Coverage on Tandem Diabetes Care With Neutral Rating, $45 Price Target	23-03-29	MT

More recommendations

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

44.72 USD

Average target price

44.43 USD

Spread / Average Target

-0.65%

High Price Target

60 USD

Spread / Highest target

+34.17%

Low Price Target

18 USD

Spread / Lowest Target

-59.75%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Tandem Diabetes Care, Inc.

UBS
Wells Fargo Securities
Leerink Partners
Stifel Nicolaus
Citigroup
TD Cowen
BofA Securities
Jefferies & Co.
Baird
Barclays
Craig-Hallum
Raymond James
Cowen
Piper Sandler
Wolfe Research
Lake Street
Oppenheimer
SVB Leerink
Berenberg Bank

Ratings for Tandem Diabetes Care, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar